Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.045
+0.025 (2.45%)
Jun 27, 2025, 12:41 PM - Market open
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
$853,862
Profits / Employee
-$504,020
Market Cap
207.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ESPR News
- 13 days ago - Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha
- 6 weeks ago - Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - GlobeNewsWire
- 7 weeks ago - Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference - GlobeNewsWire
- 7 weeks ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada - GlobeNewsWire
- 7 weeks ago - Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Esperion to Participate in The Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025 - GlobeNewsWire